CEPH Message Board - Msg: 2497332

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CEPH

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: WeirdPro Randy who wrote (470)	10/20/1997 6:14:00 PM
From: IN_GOD_I_TRUST	of 998

Positive news on CEPH.... Monday October 20 2:01 PM EDT Cephalon gets UK nod for narcolepsy drug WEST CHESTER, Pa., Oct 20 (Reuters) - Cephalon Inc said Monday its U.K. subsidiary has been granted a license by the Medicines Control Agency to market Provigil (modafinil) tablets in the United Kingdom for the treatment of narcolepsy. Modafinil is an non-amphetamine agent that Cephalon is developing for the treatment of excessive daytime sleepiness associated with narcolepsy under a license from Laboratoire L. Lafon, the French pharmaceutical company which discovered and currently markets the drug in France. Cephalon has exclusive rights to market modafinil in the United States, Japan, the United Kingdom, Ireland and Mexico. Marketing applications are currently pending in the United States and Ireland. Cephalon said it intends to manufacture Provigil tablets in the United States and launch the drug in the United Kingdom upon Medicines Control Agency approval of these manufacturing arrangements. ------------------------------------------------------------------------ More news for referenced ticker symbols: CEPH, and related categories and industries: healthcare, stock capsules.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next